The new Parachute device is a new minimally invasive treatment option available for patients with heart failure compared to other traditional invasive surgical treatments available.

By inserting a small catheter in the femoral artery, the Parachute ventricular partitioning device is deployed into the left ventricle to partition the damaged muscle, separating the non-functional heart segment from the healthy, functioning segment.

This minimally invasive procedure decreases the overall volume of the left ventricle and restores its geometry and function.

Institut Jantung Negara (National Heart Institute) in Kuala Lumpur, Malaysia CEO Dr Robaayah Zambahari noted the institute is thrilled that the first Parachute procedure in Asia was performed in Kuala Lumpur.

"The Parachute device is an innovative new option that has demonstrated promising results in previous studies," Dr Zambahari added.

While the Parachute received CE Mark in 2011, it is still an investigational device in the US and is currently enrolling patients for the US pivotal study, PARACHUTE IV.

CardioKinetix president and CEO Maria Sainz noted the expansion of the Parachute device into Asia is an important achievement for the company.

"Continuing to partner with leading clinicians and heart centers illustrates the promise the Parachute holds to bring a solution for the underserved heart failure patients around the world," Sainz added.